Intercell Does Not Leave the Loss zone

Business › n.a. ♦ Published: March 6, 2012; 13:02 ♦ (Vindobona)

The Austrian pharmaceutical company announces preliminary full year 2011 financial results. Losses totaled € 29m.

Intercell Does Not Leave the Loss zone / Picture: © Intercell

Intercell noted total revenues of € 32.9m in 2011 compared to € 34.2m in 2010, which is due to lower collaboration revenues. In the last quarter of 2011, revenues reached € 6.98m, after € 13.1m in 2010. The company decided to reduce R&D expenses by 60.0% to € 29.9m and SG&A expenses by 20.1% to € 15.8m.

Net loss reached € 29.3m in the year 2011, compared to…

or Log In

Fast News Search
Related News
Intercell Plans to Achieve Turnaround in 2014 (February 6, 2012)
New Chairman for Intercell’s Supervisory Board (December 30, 2011)
Intercell Receives Approval for Vaccine in India (November 10, 2011)
Intercell Still Reports Losses (November 8, 2011)
R&D Expenses on the Rise (October 24, 2011)
Read More
Intercell, Earnings, Pharmaceutical Industry
Featured
Coronavirus in Austria: Update
Coronavirus Situation at the Vienna International Centre (VIC): Live-Ticker - New COVID-19 Case at the IAEA
See latest Vindobona Newsletter